

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: September 14, 2022 Administrative Circular: 2022:37

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Footnote B was revised to remove pregnant persons from those who may receive a booster dose 8 weeks after completion of the primary series.

Please remove page numbers: 1-3 dated September 8, 2022 Please add new page numbers: 1-3 dated September 14, 2022

The following COVID-19 vaccine product pages have been updated to indicate the following:

Doses and Schedule:

Content has been revised to indicate that the minimum interval between completion of the primary series and the booster dose is 3 months. This revised minimum interval additionally applies to pregnant people and aligns with the National Advisory Committee on Immunization's <u>Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding</u>. The exception to this is the Janssen vaccine for which the minimum interval is 8 weeks between the single dose of Janssen vaccine and the booster dose.

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)

In addition to the revision to the Doses and Schedule indicated above the Product Components have been corrected to include tromethamine and tromethamine hydrochloride.

Please remove page numbers: 1-5 dated September 8, 2022 Please add new page numbers: 1-5 dated September 14, 2022





COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)

Please remove page numbers: 1-5 dated September 8, 2022 Please add new page numbers: 1-5 dated September 14, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older (Red Vial Cap)

Please remove page numbers: 1-5 dated September 8, 2022 Please add new page numbers: 1-5 dated September 14, 2022

COVID-19 mRNA Vaccine Spikevax™ Bivalent (Moderna)

Please remove page numbers: 1-4 dated September 8, 2022 Please add new page numbers: 1-4 dated September 14, 2022

The following COVID-19 vaccine product pages have been updated to indicate the following:

Booster Doses:

Content has been revised to indicate that the minimum interval between completion of the primary series and the booster dose is 3 months. This revised minimum interval additionally applies to pregnant people and aligns with the National Advisory Committee on Immunization's <u>Updated guidance on</u> COVID-19 vaccines for individuals who are pregnant or breastfeeding.

COVID-19 Vaccine VAXZEVRIA™ (AstraZeneca)

Please remove page numbers: 1-4 dated September 8, 2022 Please add new page numbers: 1-4 dated September 14, 2022

COVID-19 Vaccine NUVAXOVID™ (Novavax)

Please remove page numbers: 1-3 dated September 8, 2022 Please add new page numbers: 1-3 dated September 14, 2022





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

Medical Director

Communicable Diseases & Immunization Service

BC Centre for Disease Control

dite bans

pc:

Provincial Health Officer

Dr. Bonnie Henry

BC Ministry of Health,

Population & Public Health Division:

Brian Sagar

Senior Director Communicable Disease,

Population and Public Health Division

Bernard Achampong

Executive Director,

Public Health, Planning and Prevention,

Population and Public Health Division



